Research programme: 15-lipoxygenase inhibitors - Orexo/Johnson & Johnson Innovative Medicine/Janssen Pharmaceutica
Alternative Names: BLX 2477; OX 2477; OX-ESILatest Information Update: 10 Oct 2023
At a glance
- Originator Biolipox
- Developer Orexo
- Class Anti-inflammatories
- Mechanism of Action 15-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 01 Feb 2012 Discontinued - Preclinical for Asthma in Sweden (PO)
- 01 Feb 2012 Discontinued - Preclinical for Chronic obstructive pulmonary disease in Sweden (PO)